



New Study Shows Promising Results in Predicting Scoliosis Progression from 3D imaging

*Data Presented at SRS Conference Suggest 3D Evaluation May Help Forecast Disease
Progression at Initial Medical Visit*

Paris, 10 September 2012 - EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announces today results of a new clinical study highlighting the value of 3D spine measurements provided by the EOS® imaging system for monitoring and predicting scoliosis progression as of the patient's first medical visit. The data was presented at the 47th annual conference of the Scoliosis Research Society (SRS).

Dr. Stefan Parent, of Sainte-Justine Hospital in Montreal and lead investigator, says, *"This study sheds new light on the benefits of the EOS 3D technology in more precisely assessing and predicting the progression of scoliosis. The 3D parameters measured using EOS improve our ability to choose the most appropriate treatment path for our adolescent patients, whether it be monitoring, use of a brace or surgery. This is a considerable benefit for the surgeon and especially for the patient."*

The prospective study, financed by the Canadian Institutes of Health Research and the FRSQ (Fonds de recherche en Santé du Québec, the Quebec Health Research Fund), involved 134 patients with Adolescent Idiopathic Scoliosis (AIS). The findings demonstrated that the 3D morphological parameters of the spine obtained with EOS® can be used to distinguish between progressive scoliosis and non-progressive scoliosis from the point of the first medical visit. Such a distinction is not possible on the basis of two-dimensional parameters. The propensity of scoliosis to develop and worsen, or not, is a major challenge when choosing therapies, which are costly and invasive.

Marie Meynadier, CEO of EOS imaging, says, *"Scoliosis, which has long been detected and monitored in 2D, can now benefit from these very significant results, which might improve the care pathway, benefiting both patients and healthcare systems. This study, which was presented during a major conference for the profession, strengthens the visibility of EOS among orthopaedic professionals and its clinical value to improve care for their patients."*

For further information about the Company or EOS®, the first full-body, low-dose 3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 47 sites and more than 150,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 59 people, including an R&D team of 21 engineers and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge (Massachusetts), in Montreal (Canada) and in Germany.



EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2012 on 15 November 2012 (after market).

Contacts :

Anne Renevot
Directeur Financier
Tél. : +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.
Communication financière et relations investisseurs
Sophie Boulila / Pierre Laurent
Tél. : +33 (0)1 44 71 94 91 – eosimaging@newcap.fr

ALIZE RP
Relations presse Caroline Carmagnol
Tél : +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com